1. Home
  2. AXR vs ACRS Comparison

AXR vs ACRS Comparison

Compare AXR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AXR
  • ACRS
  • Stock Information
  • Founded
  • AXR 1961
  • ACRS 2012
  • Country
  • AXR United States
  • ACRS United States
  • Employees
  • AXR N/A
  • ACRS N/A
  • Industry
  • AXR Homebuilding
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AXR Real Estate
  • ACRS Health Care
  • Exchange
  • AXR Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • AXR 120.0M
  • ACRS 137.5M
  • IPO Year
  • AXR N/A
  • ACRS 2015
  • Fundamental
  • Price
  • AXR $20.60
  • ACRS $1.49
  • Analyst Decision
  • AXR
  • ACRS Strong Buy
  • Analyst Count
  • AXR 0
  • ACRS 8
  • Target Price
  • AXR N/A
  • ACRS $9.71
  • AVG Volume (30 Days)
  • AXR 13.5K
  • ACRS 709.4K
  • Earning Date
  • AXR 07-22-2025
  • ACRS 05-08-2025
  • Dividend Yield
  • AXR N/A
  • ACRS N/A
  • EPS Growth
  • AXR 472.07
  • ACRS N/A
  • EPS
  • AXR 2.41
  • ACRS N/A
  • Revenue
  • AXR $58,052,000.00
  • ACRS $17,777,000.00
  • Revenue This Year
  • AXR N/A
  • ACRS N/A
  • Revenue Next Year
  • AXR N/A
  • ACRS $14.59
  • P/E Ratio
  • AXR $8.41
  • ACRS N/A
  • Revenue Growth
  • AXR 30.35
  • ACRS N/A
  • 52 Week Low
  • AXR $15.88
  • ACRS $0.99
  • 52 Week High
  • AXR $39.68
  • ACRS $5.17
  • Technical
  • Relative Strength Index (RSI)
  • AXR 42.64
  • ACRS 63.24
  • Support Level
  • AXR $19.60
  • ACRS $1.22
  • Resistance Level
  • AXR $21.60
  • ACRS $1.56
  • Average True Range (ATR)
  • AXR 1.21
  • ACRS 0.09
  • MACD
  • AXR -0.28
  • ACRS 0.03
  • Stochastic Oscillator
  • AXR 28.41
  • ACRS 82.48

About AXR AMREP Corporation

Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: